Merck Asserts PD-1 inhibitor Keytruda’s Competitiveness In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Data on overall survival benefit are still maturing but biomarker data should be useful for payers and physicians, say company executives during its first-quarter analyst’s call. Merck execs also reported the company’s best-selling product Januvia is not associated with a heart failure safety signal.